Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it plans to spin off its ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...

Samsung Biologics spins off Samsung Bioepis Holdings to enhance competitiveness Samsung Bioepis Holdings aims to streamline ...

Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by ...

Samsung Biologics Logo (PRNewsfoto/Samsung Biologics) "We sustained solid momentum in the first quarter, supported by the efficient operations across all our plants and continued partnerships with our ...

Samsung Biologics' first-quarter revenue grew 37% to KRW 1.3 trillion, driven by higher contribution from the completion of Plant 4 in 2024, strong biosimilar sales, and favorable currency impact.

"We sustained solid momentum in the first quarter, supported by the efficient operations across all our plants and continued partnerships with our clients," said John Rim, CEO and President of Samsung ...